Participants , who had received 3 HPV-16 / 18 AS04-adjuvanted vaccine doses at 10-14 years of age in an initial controlled , observer-blinded , randomized study ( NCT00196924 ) and participated in the open 3-year follow-up ( NCT00316706 ) , were invited to continue the follow-up for up to 10 years postvaccination ( NCT00877877 ) .